ROCKVILLE, Md., Aug. 27,
2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX)
today announced data from its RGX-121 program for the treatment of
mucopolysaccharidosis type II (MPS II), also known as Hunter
syndrome, will be shared at the SSIEM 2024 Annual Symposium, taking
place in Porto, Portugal from
September 3-6, 2024.
Abstract Title: CAMPSIITE™ phase I/II/III: Interim
clinical update of RGX-121, an investigational gene therapy for
treatment of neuronopathic mucopolysaccharidosis type II (MPS II)
(PO-205)
Presenter: Roberto Giugliani, M.D., Ph.D., Professor,
Department of Genetics, UFRGS, Medical Genetics Service, HCPA,
Porto Alegre, Brazil
Date/Time: Wednesday, September 4, 2024; 6:15 p.m. WEST (Western European Summer Time)
About REGENXBIO Inc.
REGENXBIO is a leading
clinical-stage biotechnology company seeking to improve lives
through the curative potential of gene therapy. Since its founding
in 2009, REGENXBIO has pioneered the development of AAV
Therapeutics, an innovative class of gene therapy medicines.
REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal
and rare diseases, including ABBV-RGX-314 for the treatment of wet
AMD and diabetic retinopathy, being developed in collaboration with
AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the
treatment of MPS II. Thousands of patients have been treated with
REGENXBIO's AAV Therapeutic platform, including Novartis'
ZOLGENSMA® for children with spinal muscular atrophy.
Designed to be one-time treatments, AAV Therapeutics have the
potential to change the way healthcare is delivered for millions of
people. For more information, please visit www.regenxbio.com.
Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com
Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-the-society-for-the-study-of-inborn-errors-of-metabolism-ssiem-2024-annual-symposium-302231163.html
SOURCE REGENXBIO Inc.